Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: Reversed by anti-TNF-alpha treatment

Autores de CIPF

• Tiziano Balzano

  Autor

• Sherry Dadsetan

  Autor

• Jerónimo Forteza Vila

  Autor

• Andrea Cabrera Pastor

  Autor

• Lucas Taoro González

  Autor

• Michele Malaguarnera

  Autor

• 

  Yaiza Arenas Ortiz

  Autor

• Paola Leone

  Autor

• 

  Slaven Erceg Vukicevic

  Autor

• 

  Marta Llansola Gil

  Autor

• 

  Vicente Felipo Orts

  Autor

Participantes ajenos a CIPF

• Gil-Perotin, S
• Cubas-Nunez, L
• Casanova, B
• Castro-Quintas, A
• Ponce-Mora, A

Grupos de Investigación

• Laboratorio de Neurobiología

  

  Jefe/a de Grupo

  Vicente Felipo Orts

• Laboratorio Terapias con Células Madre en Enfermedades Neurodegenerativas

  

  Jefe/a de Grupo

  Slaven Erceg Vukicevic

Abstract

Background & Aims: Chronic hyperammonemia induces neuroinflammation which mediates cognitive impairment. How hyperammonemia induces neuroinflammation remains unclear. We aimed to assess whether: chronic hyperammonemia induces peripheral inflammation, and whether this then contributes to neuroinflammation, altered neurotransmission and impaired spatial learning-before assessing whether this neuroinflammation and impairment is reversible following hyperammonemia elimination or treatment of peripheral inflammation with anti-TNF-alpha. Methods: Chronic hyperammonemia was induced by feeding rats an ammonia-containing diet. Peripheral inflammation was analyzed by measuring PGE2, TNF-alpha, IL-6 and IL-10. We tested whether chronic anti-TNF-alpha treatment improves peripheral inflammation, neuroinflammation, membrane expression of glutamate receptors in the hippocampus and spatial learning. Results: Hyperammonemic rats show a rapid and reversible induction of peripheral inflammation, with increased proinflammatory PGE2, TNF-alpha and IL-6, followed at around 10 days by reduced anti-inflammatory IL-10. Peripheral anti-TNF-alpha treatment prevents peripheral inflammation induction and the increase in IL-1b and TNF-alpha and microglia activation in hippocampus of the rats, which remain hyperammonemic. This is associated with prevention of the altered membrane expression of glutamate receptors and of the impairment of spatial memory assessed in the radial and Morris water mazes. Conclusions: This report unveils a new mechanism by which chronic hyperammonemia induces neurological alterations: induction of peripheral inflammation. This suggests that reducing peripheral inflammation by safe procedures would improve cognitive function in patients with minimal hepatic encephalopathy. Lay summary: This article unveils a new mechanism by which chronic hyperammonemia induces cognitive impairment in rats: chronic hyperammonemia per se induces peripheral inflammation, which mediates many of its effects on the brain, including induction of neuroinflammation, which alters neurotransmission, leading to cognitive impairment. It is also shown that reducing peripheral inflammation by treating rats with anti-TNF-alpha, which does not cross the blood-brain barrier, prevents hyperammonemia-induced neuroinflammation, alterations in neurotransmission and cognitive impairment. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Keywords

• Hyperammonemia; Peripheral inflammation; Hepatic encephalopathy; Neuroinflammation; Cognitive impairment